ClinicalTrials.gg
RecruitingNCT07005180LoCaMoTE-PDUpdated Sep 21, 2026

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

A Phase 2 interventional study of HBI-002 and Vehicle (placebo) in Parkinson Disease, sponsored by Hillhurst Biopharmaceuticals, Inc.. Recruiting at 8 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Hillhurst Biopharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
624th of 1,256
36 · median 36
Started
2026
with 82 others
Phase 2
234 of 1,649
25 open now
Primary completion
2026-12
later than 101 of 383 live
Registered
1,510th of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 624th largest by planned enrollment of the 1,256 interventional ones that give a count, is one of 83 that started in 2026, is one of 234 in phase 2, reaches primary completion later than 101 of the 383 other live ones, and was the 1,510th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson Disease
  • HBI-002
  • low dose carbon monoxide
  • heme oxygenase
  • HO-1
  • Nrf2
  • HIF-1α
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet the following criteria before being enrolled into the study:

  1. Signed .
  2. Male or female 40-80 years of age
  3. Non-smoker for at least 5 years with smoking defined as the use of smoked products (e.g. tobacco, marijuana, vaping or other)
  4. No smoking in the home (i.e. not living with a smoker)
  5. Body weight between 60 kg and 110 kg (inclusive) and with less than 30 kg/m2 at screening and baseline
  6. Diagnosis of PD according to the Movement Disorder Society within 60 months of screening
  7. Hoehn and Yahr stage ≤ 3
  8. PD therapy: use of ≥100 mg TID levodopa or equivalent dose with additional carbidopa/levodopa or other antiparkinsonian medication (e.g. dopamine agonists [e.g., pramipexole, ropinirole, rotigotine] and monoamine oxidase inhibitors [e.g., selegiline or rasagiline]) for ≥30 days of stable dosing
  9. Good clinical response to levodopa therapy in the Site Investigator's opinion
  10. Negative pregnancy test for females of
  11. Where appropriate, subjects must be willing to use a highly effective method of for the duration of the study and for 45 days thereafter

    1. Male subjects, without a vasectomy, whose partner is of childbearing potential, must use a condom and be instructed that their female partner should use another form of contraception such as an IUD, diaphragm with spermicide, oral contraceptive, injectable progesterone, subdermal implant or a tubal ligation. Male subjects are prohibited from donating sperm for the duration of the study and 60 days following the end of study visit.
    2. Female subjects of childbearing potential (not surgically sterilized and less than one year ) should use a medically accepted form of contraception such as an IUD, diaphragm with spermicide, oral contraceptive, injectable progesterone, subdermal implant or a tubal ligation, and be instructed that their male partners should use a condom, if not vasectomized.
  12. Subjects must be healthy as defined by the following.

    1. liver function: (ALT) and aspartate transaminase (AST) ≤ 2X
    2. total ≤ 1.5X ULN
    3. renal function: within normal range as assessed by Cockcroft and Gault calculation
    4. carboxyhemoglobin level by venous blood gas ≤ 3.5%
    5. the absence of current abnormalities identified by a detailed medical history, full physical examination including blood pressure, pulse rate, and respiratory rate measurement, 12-lead , and clinical laboratory tests (hematology and clinical chemistries), as determined by the Site Investigator.
    6. \< 6.5%
  13. Subjects must have a study partner who can observe the subject for at least 4 hours after dosing at home (non-clinic days) in order to monitor for indications of CO toxicity.
  14. Subjects should live within 100 miles driving distance (door to door) of the site/clinic due to the need to carry study drug and ship study drug between the site/clinic and subject's home. Exceptions to this may be considered with Sponsor approval if it can be assured that the subject can transport study drug from clinic to home within two hours.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will be ineligible for participation in the study:

  1. Clinical signs indicating a parkinsonian syndrome other than idiopathic PD, specifically:

    1. Atypical parkinsonism, including parkinsonism due to drugs, metabolic disorders, encephalitis, cerebrovascular disease, normal pressure hydrocephalus, or other neurodegenerative disease.
    2. Supranuclear gaze palsy
    3. Signs of dementia ( \< 22)
    4. History of repeated strokes with stepwise progression of parkinsonian features
    5. History of repeated head injury
    6. History of definite encephalitis
    7. Cerebellar signs
    8. Early severe autonomic involvement
    9. Babinski sign present
  2. Dysphagia with liquids
  3. History of exposure to or current treatment with neuroleptic drugs.
  4. History of dementia
  5. Oxygen saturation by transcutaneous measurement ≤ 95% confirmed on repeat assessment (any time prior to the first dose)
  6. abnormalities (prolonged greater than normal range, arrhythmia detected, bradycardia \<45 bpm, tachycardia >120 bpm, AV block [second or greater degree], bundle branch block) or vital sign abnormalities (systolic blood pressure lower than 90 or above 140 mm Hg, diastolic blood pressure lower than 50 or above 90 mm Hg, or heart rate less than 45 or above 100 bpm or arrhythmia), as determined by the Site Investigator.
  7. Renal failure requiring renal replacement therapy
  8. History of:

    1. Serious cardiovascular diseases

      • History of angina pectoris
      • History of myocardial infarction or cardiac failure ( from II to IV), myocardial insufficiency, symptomatic congestive heart failure with a documented below 45%
      • History of serious cardiac arrhythmia other than stable atrial fibrillation
      • History of stroke or occlusive peripheral vascular disease, brain vasospasm
    2. Structural brain disease or cerebrovascular disease with clinical significance, including intracranial space-occupying lesion
    3. Severe uncontrolled arterial hypertension
    4. Severe pulmonary disease (asthma, , other)
    5. Specific psychiatric disorders, including hallucinations, delusions, pathologic gambling, alcohol or substance abuse or dependence
    6. Type 1 or type 2 diabetes mellitus, impaired glucose tolerance, metabolic syndrome, maturity onset diabetes of the young, and gestational diabetes.
    7. Pulmonary infiltrate or pneumonia within 6 months before screening or acute infection within 14 days of screening
    8. Seizures / epilepsy
    9. disease requiring prescribed immunomodulatory therapy
  9. Alcohol abuse or dependence within one year prior to screening or regular use of alcohol within six months prior to the screening visit (defined as more than 14 units of alcohol per week; 1 Unit = 150 mL wine, 360 mL beer or 45 mL of 40% alcohol)
  10. History of drug abuse or dependence
  11. Positive result on drug screen for THC, cocaine, opiates/opioids, and methamphetamine
  12. History of cancer, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin more than 3 months prior
  13. Subject on domiciliary oxygen
  14. Positive , aHCV, or aHIV
  15. Positive SARS-CoV-2 test within 10 days prior to study drug treatment
  16. Weight loss or gain of more than 5 kg within 3 months of screening
  17. Febrile or infective illness within 10 days prior to study drug treatment
  18. Moderate or more severe depression (Geriatric Depression Scale (GDS) ≥9)
  19. Suicide attempt or suicidal ideation within five years (Columbia-Suicide Severity Rating Scale (C-SSRS) defined as answering yes to items 4 or 5 on the C-SSRS, or history of suicide attempt in previous 5 years, or, in the Investigator's opinion, at serious risk of suicide.
  20. Positive pregnancy test or breast feeding for females
  21. Treatment with an drug or medical device within the longer of 60 days or ten half-lives of the investigational agent
  22. Simultaneous participation or previous participation within 60 days before screening in another clinical drug or medical device study
  23. Persisting anemia with \<9 g/dL
  24. Blood transfusion within 42 days prior to the first administration of study drug
  25. Exposure to any within 28 days prior to study drug administration
  26. Syncope or other cause of loss of consciousness within the last 2 years
  27. Unwilling or unable to respond to follow-up phone calls
  28. Unwilling or unable to communicate with study site staff by telephone
  29. Unwilling or unable to comply with the requirements of the protocol
  30. Any coincident disease or condition that in the opinion of the Site Investigator will confound the assessment of HBI-002 safety or efficacy
  31. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Site Investigator, would make the subject inappropriate for entry into the study
  32. History of allergic reactions to any of the drug product
  33. to a routine lumbar puncture

    1. History of thrombocytopenia ( count \<100,000)
    2. History of coagulopathy ( >1.3, PTT >)
    3. Current use of warfarin or other anticoagulants, or clopidogrel (Plavix)
    4. History of lumbar surgery or severe spinal arthritis
    5. Infection at LP site (may be included once resolved)
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    High Dose

    Drug: HBI-002

  • Experimental
    Low Dose

    Drug: HBI-002

  • Placebo comparator
    Placebo

    Drug: Vehicle (placebo)

Interventions

  • Oral liquid containing carbon monoxide

  • DrugVehicle (placebo)

    Vehicle control (placebo)

06

What researchers measure

Primary outcomes

  1. Frequency and severity of treatment-emergent AEs related to HBI-002 compared to placebo.

    Time frame: From treatment to 30 days after the end of treatment

Secondary outcomes

  1. Pharmacokinetics as measured by carboxyhemoglobin (COHb) levels

    Time frame: Days 1 and 14

07

Study locations

5 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

Of 96 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's planned 6 months is below that.

Counting every sponsor, half of 201 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2025
First posted
Jun 5, 2025
StartActual
Jun 30, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07005180
Lead sponsor
Hillhurst Biopharmaceuticals, Inc.
Collaborators
The Parkinson Study Group, Massachusetts General Hospital (PI: Michael Schwarzschild MD,PhD, Co-PI: Stephen Gomperts MD,PhD), Michael J. Fox Foundation for Parkinson's Research
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Jun 30, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

President and CEO
Contact
hillhurstinfo@hillhurstbio.com
858-232-9495

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBI-002

Start the discussion